June 3, 2013 — ERT has introduced a centralized Ambulatory Blood Pressure Monitoring (ABPM) solution. ABPM enables biopharmaceutical companies to efficiently evaluate the efficacy and cardiac safety of both hypertensive and anti-hypertensive drugs as well as endpoints for cardiovascular and cerebrovascular outcomes.
The ABPM solution is an extension of ERT’s suite of centralized cardiac safety solutions and services. The solution utilizes the Mortara Ambulo 2400 monitor, which is validated to stringent clinical accuracy standards. Based on patented, oscillometric technology and built-in actigraphy for automatic categorization of sleep/awake cycles, ERT’s ABPM solution captures accurate 24-hour readings of systolic and diastolic blood pressure, mean arterial pressure, and pulse rate.
“Mortara is excited to expand its relationship with ERT to include our Ambulo technology in their ABPM solution. In analyzing past practices for centralized ABPM, we identified significant opportunities for innovation to create a solution that was better tuned to the needs of clinical trials. Mortara’s ABPM platform is that solution,” said Justin Mortara, CEO, Mortara Instrument.
ERT’s ABPM solution includes a seamless, digital data transfer process that eliminates the collection of erroneous site, patient and visit information. It enables clinical trial sponsors to benefit from increased reporting efficiencies and to further reduce site burden by integrating ABPM with electrocardiogram (ECG) and Holter services. Trial sponsors will also benefit from an efficient project assurance process; integrated device logistics and supply management; integrated demography and visit checks; and integrated data management and delivery, including access to reports on My Study Portal, ERT's integrated study portal.
For more information: www.ert.com, www.mortara.com